Calcitonin

• However, even in Canada, with a universal health-care system, migraine is underdiagnosed and undertreated.
• Policymakers need to act now to remove the barriers to accessing migraine medications in Canada, particularly as new medications are marketed.

What is migraine?

• Pain typically affects one side of the head and presents with nausea or vomiting, sensitivity to light or sound and interference with routine physical activity.
• Migraine can be episodic (fewer than 15 headache days per month) or chronic (15 or more headache days per month for longer than three months).

Impact of migraine

• Migraine is associated with lost productivity and with other health conditions including asthma, epilepsy and cardiovascular disease.
• Furthermore, migraine can contribute to mental health problems, including depression and anxiety.
• Canada is no stranger to this trend, where migraine affects 4.7 per cent of men and 11.8 per cent of women each year.

Historically, migraine has been underdiagnosed

• Factors influencing diagnosis include an individual’s ability and willingness to access care, and a physician identifying and correctly diagnosing migraine.
• However, research has demonstrated that for chronic migraine, most individuals report consulting a physician about their headaches.
• This suggests that in people with chronic migraine specifically, underdiagnosis may be driven by the failure to receive a correct diagnosis from a health-care provider.

Migraine-specific medications are under-used

• Triptans are among the oldest migraine-specific medications, and the first-line treatment for migraine for those who do not get relief from over-the-counter medications.
• Despite this, many individuals living with migraine in Canada do not use or have not tried migraine-specific medications.
• As new migraine-specific medications are approved in Canada, it is important that those who need them can access these treatments.
• These medications are used to prevent migrainous headaches, and cost over $600 per month.

Steps you can take if you think you might have migraine

• Migraine Buddy is a migraine tracking app with a questionnaire to help individuals determine if they may have migraine and should discuss their symptoms with a physician.
• Effective treatment options exist to manage migraine, which can be accessed through a physician.

• As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.
• Drivers of royalty receipts in the first quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
• Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
• Royalty Pharma will also receive 25% of Ionis’ mid-teens to low-20% royalty on net sales of pelacarsen, resulting in a mid-single digit royalty to Royalty Pharma.

• Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP).
• Target to address unmet medical needs for millions of Chinese migraine patients.
• A new drug application for Galcanezumab as a preventative treatment for episodic migraine in adults was submitted by Eli Lilly to China's National Medical Products Administration ("NMPA") in June 2022.
• Significantly greater mean proportions of patients with galcanezumab versus placebo had ≥ 50%, ≥ 75%, and 100% reductions from baseline in MHDs (all p

• The Global Peptide Therapeutics Market is segmented based on Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography.
• The report presents a detailed Ansoff matrix analysis for the Global Peptide Therapeutics Market.
• The analyst analyses the Global Peptide Therapeutics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
• Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.